Accepted Manuscript

Emerging Therapies for Atopic Dermatitis: The Prostaglandin/Leukotriene Pathway

Daniel A. Yanes, MD, Joy L. Mosser-Goldfarb, MD

PII: S0190-9622(17)32822-0

DOI: 10.1016/j.jaad.2017.12.021

Reference: YMJD 12182

To appear in: Journal of the American Academy of Dermatology

Received Date: 10 November 2017

Revised Date: 8 December 2017

Accepted Date: 9 December 2017

Please cite this article as: Yanes DA, Mosser-Goldfarb JL, Emerging Therapies for Atopic Dermatitis: The Prostaglandin/Leukotriene Pathway, *Journal of the American Academy of Dermatology* (2018), doi: 10.1016/j.jaad.2017.12.021.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



- 1 Article Type: Original
- 2 Title: Emerging Therapies for Atopic Dermatitis: The Prostaglandin/Leukotriene
- 3 Pathway
- 4 Yanes, Daniel A, MD¹, Mosser-Goldfarb, Joy L, MD¹
- ¹Division of Dermatology
- 6 Department of Pediatrics
- 7 Nationwide Children's Hospital
- 8 Columbus, OH 43205, USA.
- 9 <u>dermjoy@aol.com</u>
- 10 Funding Sources: Bayer, LEO Pharma, Sanofi
- 11 IRB approval status: N/A
- 12 Clinicaltrials.gov (or equivalent) listing (if applicable): N/A
- 13 Conflicts of Interest:
- 14 Joy Mosser-Goldfarb, MD: None
- 15 Daniel A. Yanes, MD: None
- 16 Reprint requests: n/a
- 17 Manuscript word count: 1,528 words
- 18 Abstract word count: 147
- 19 Capsule summary word count: 50
- 20 References: 26
- 21 Figures: 1
- 22 Supplementary figures: n/a
- 23 Tables: 1

Download English Version:

https://daneshyari.com/en/article/8715283

Download Persian Version:

https://daneshyari.com/article/8715283

Daneshyari.com